Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS ...

September 15, 2024

Early switch to atezolizumab after vemurafenib plus cobimetinib in BRAF V600-positive melanoma showed improved OS at 4 and 5 years in the ImmunoCobiVem trial, but not statistically significant. Rapid progression after switch to immune checkpoint inhibition was observed in some patients.

Related Clinical Trials

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Reference News

onclive.com

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS ...